Preliminary results from PROPEL: A phase I/II study of bempegaldesleukin (BEMPEG: NKTR-214) plus pembrolizumab (PEMBRO) with or without chemotherapy in patients with metastatic NSCLC Article

Full Text via DOI: 10.1016/j.annonc.2021.10.159 Web of Science: 000731051400143
Industry Collaboration International Collaboration

Cited authors

  • Felip E, Spigel DR, Vidal OJJ, Beck JT, de la Rosa CA, Johnson DH, Spath-Schwalbe E, Reinacher-Schick A, Abreu DR, Altan M, Reinmuth N, Edelman MJ, Reck M, Zhao Q, Banerjee S, Chaudhry S, Chien D, Tagliaferri MA, Zalevsky J, Ganti A

Publication date

  • 2021

Published in


International Standard Serial Number (ISSN)

  • 0923-7534

Number of pages

  • 4

Start page

  • S1438

End page

  • S1440


  • 32